Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Litigation is a launch cost, and earnings season is finally pricing it that way

Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.

16 Nov 2026 · CompePharma editorial

The number below the line

Liquidia's third quarter has two headlines that barely seem to describe the same company. YUTREPIA net product sales reached $222.7 million, up 31% from the second quarter. Adjusted EBITDA rose for a fifth consecutive quarter to $140.5 million. Yet the company booked a net loss of $236.3 million, because of a $389.7 million litigation settlement charge.

That charge is larger than the quarter's entire net product sales and more than two and a half times the adjusted EBITDA the company is proud of. Liquidia says the global settlement with United Therapeutics resolves all litigation and secures continuity of care for patients on YUTREPIA. October shipments were the highest monthly level since launch. That is a real commercial success, but it is not the whole economic story.

Our view is that the cost of securing the right to sell a product is part of what the product earns. Adjusted metrics that routinely set it aside flatter the launch, and this season's results show the gap getting too wide to ignore.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →
Opinion · CompePharma View

A guidance raise is only as good as who controls the trigger

Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.

15 Nov 2026 · CompePharma editorial